help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on October 3, 2002, doi:10.1164/rccm.200207-747OC

Am. J. Respir. Crit. Care Med., Volume 167, Number 3, February 2003, 379-383

A more recent version of this article appeared on February 1, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200207-747OCv1
167/3/379    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bisgaard, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bisgaard, H.

Submitted on July 25, 2002
Accepted on October 2, 2002

A RANDOMISED TRIAL OF MONTELUKAST IN RESPIRATORY SYNCYTIAL VIRUS POST-BRONCHIOLITIS

Hans Bisgaard1*

1 Pediatrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

* To whom correspondence should be addressed. E-mail: bisgaard{at}copsac.dk.

Infants often develop reactive airway disease (RAD) after respiratory syncytial virus (RSV) bronchiolitis. Cysteinyl-leukotrienes (cys-LT) are released during RSV infection and may contribute to the inflammation. We hypothesized that a cys-LT receptor antagonist would ameliorate RAD subsequent to RSV bronchiolitis. One hundred and thirty infants of 3-36 months, hospitalized with acute RSV bronchiolitis were randomized into a double-blind, parallel comparison of 5 mg montelukast chewable tablets or matching placebo given for 28 days starting up to 7 days after symptom debut. Children with a suspected history of asthma were excluded. One hundred and sixteen infants provided diary card data for the treatment period. Median age was 9 months. Infants on montelukast were free of any symptoms on 22% of the days and nights compared to 4% of the days and nights in children on placebo (p=0.015). Day-time cough was significantly reduced on active treatment (p=0.04). Exacerbations were significantly delayed from montelukast compared with placebo (p<0.05). In conclusion, cys-LT antagonist treatment reduces lung symptoms subsequent to RSV bronchiolitis.
Key words: bronchial hyperresponsiveness, infant, leukotriene receptor antagonist, respiratory syncytial virus




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
A. Bush
Update in Pediatric Lung Disease 2008
Am. J. Respir. Crit. Care Med., April 15, 2009; 179(8): 637 - 649.
[Full Text] [PDF]

Home page
 BMJHome page
M. J J Ermers, M. M Rovers, J. B van Woensel, J. L L Kimpen, L. J Bont, and on behalf of the RSV Corticosteroid Study Group
The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial
BMJ, March 31, 2009; 338(mar31_2): b897 - b897.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
I. Amirav, A. S. Luder, N. Kruger, Y. Borovitch, I. Babai, D. Miron, M. Zuker, G. Tal, and A. Mandelberg
A Double-Blind, Placebo-Controlled, Randomized Trial of Montelukast for Acute Bronchiolitis
Pediatrics, December 1, 2008; 122(6): e1249 - e1255.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. Bisgaard, A. Flores-Nunez, A. Goh, P. Azimi, A. Halkas, M.-P. Malice, J.-L. Marchal, S. B. Dass, T. F. Reiss, and B. A. Knorr
Study of Montelukast for the Treatment of Respiratory Symptoms of Post-Respiratory Syncytial Virus Bronchiolitis in Children
Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 854 - 860.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
G. L. Kearns, S. Lu, L. Maganti, X. Li, E. Migoya, T. Ahmed, B. Knorr, and T. F. Reiss
Pharmacokinetics and Safety of Montelukast Oral Granules in Children 1 to 3 Months of Age With Bronchiolitis
J. Clin. Pharmacol., April 1, 2008; 48(4): 502 - 511.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
A. Bush and A. H Thomson
Acute bronchiolitis
BMJ, November 17, 2007; 335(7628): 1037 - 1041.
[Full Text] [PDF]

Home page
 NEJMHome page
M. Peters-Golden and W. R. Henderson Jr.
Leukotrienes
N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
D. Proud and C.-W. Chow
Role of Viral Infections in Asthma and Chronic Obstructive Pulmonary Disease
Am. J. Respir. Cell Mol. Biol., November 1, 2006; 35(5): 513 - 518.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
B. Knorr, L. Maganti, R. Ramakrishnan, C. A. Tozzi, E. Migoya, and G. Kearns
Pharmacokinetics and safety of montelukast in children aged 3 to 6 months.
J. Clin. Pharmacol., June 1, 2006; 46(6): 620 - 627.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A Bush
Coughs and wheezes spread diseases: but what about the environment?
Thorax, May 1, 2006; 61(5): 367 - 369.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. Crimi, C. Mastruzzo, and C. Vancheri
Bradykinin and Tachykinin-induced Leukotriene Release in Airway Virus Infections
Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 511 - 511.
[Full Text] [PDF]

Home page
 ChestHome page
W. Busse and M. Kraft
Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy
Chest, April 1, 2005; 127(4): 1312 - 1326.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. Bisgaard, S. Zielen, M. L. Garcia-Garcia, S. L. Johnston, L. Gilles, J. Menten, C. A. Tozzi, and P. Polos
Montelukast Reduces Asthma Exacerbations in 2- to 5-Year-Old Children with Intermittent Asthma
Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 315 - 322.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
L Jayaram, E Pizzichini, C Lemiere, S F P Man, A Cartier, F E Hargreave, and M M M Pizzichini
Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast
Thorax, February 1, 2005; 60(2): 100 - 105.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
G. Riccioni, C. Di Ilio, P. Conti, T. C. Theoharides, and N. D'Orazio
Advances in Therapy with Antileukotriene Drugs
Ann. Clin. Lab. Sci., October 1, 2004; 34(4): 379 - 387.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
W W Busse and R F Lemanske Jr
Management of asthma exacerbations
Thorax, July 1, 2004; 59(7): 545 - 546.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. A. Lopez-Andreu, I. Cortell-Aznar, V. Ruiz-Garcia, and H. Bisgaard
Montelukast in Respiratory Syncytial Virus Postbronchiolitis
Am. J. Respir. Crit. Care Med., June 1, 2004; 169(11): 1255 - 1256.
[Full Text]

Home page
 Clin. Microbiol. Rev.Home page
A. J. Easton, J. B. Domachowske, and H. F. Rosenberg
Animal Pneumoviruses: Molecular Genetics and Pathogenesis
Clin. Microbiol. Rev., April 1, 2004; 17(2): 390 - 412.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. Bisgaard
Montelukast in RSV-Bronchiolitis
Am. J. Respir. Crit. Care Med., February 15, 2004; 169(4): 542 - 543.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2003
Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 277 - 287.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. J. Szefler and E. A. F. Simoes
Montelukast for Respiratory Syncytial Virus Bronchiolitis: Significant Effect or Provocative Findings?
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 290 - 291.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2002 American Thoracic Society 		  ATS Clinical Skills Tests